Indicator Explainer
Cyclosporine
A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Source: National Cancer Institute, NCI Thesaurus 26.09d, C406. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-20. No individual clinical interpretation or human reviewer is asserted.
Reading results
Reference intervals and interpretation depend on the laboratory, specimen, method and clinical context. This source definition is educational information; it does not establish a diagnosis, product approval or suitability for an individual.
Also Known As
References
- NCI Thesaurus 26.09d — Cyclosporine (C406)
- Source: National Cancer Institute, NCI Thesaurus 26.09d, C406. NCI definition, reproduced without modification under CC BY 4.0.
- Epithelial uniformity pattern post topo-guided LASIK - Role of cyclosporine versus standard of care. — Indian J Ophthalmol, 2026-10-16 (PMID 42885955; literature)
- Nanomicelles self-assembled using cyclosporine A-hyaluronic acid conjugates for dry eye disease treatment. — Biomater Sci, 2026-10-13 (PMID 42764677; literature)
- Cyclosporine treatment of ARDS due to severe COVID-19: The I-SPY COVID Adaptive Platform Trial. — Ann Am Thorac Soc, 2026-10-23 (PMID 42924420; literature)
- Cyclosporine A and Romiplostim as a Bridging Therapy to Curative Surgery in Aplastic Anemia Complicated by Gastric Cancer: A Case Report. — EJHaem, 2026-10-21 (PMID 42909854; literature)
- Comparison of the In Vitro Dissolution Profiles for Cyclosporine Formulations. — J Vet Pharmacol Ther, 2026-10-21 (PMID 42908245; literature)